Facultad de Medicina (FM)
Centro académico
Université Catholique de Louvain
Louvain-la-Neuve, BélgicaUniversité Catholique de Louvain-ko ikertzaileekin lankidetzan egindako argitalpenak (31)
2024
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future oncology (London, England), Vol. 20, Núm. 13, pp. 799-809
-
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
Future Oncology, Vol. 20, Núm. 13, pp. 799-809
-
Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial
Journal of Clinical Oncology
-
Comparison of assays measuring extracellular vesicle tissue factor in plasma samples: communication from the ISTH SSC Subcommittee on Vascular Biology
Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 10, pp. 2910-2921
-
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 187, pp. 128-138
-
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
Gynecologic Oncology, Vol. 184, pp. 168-177
-
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
Journal of Prevention of Alzheimer's Disease
-
Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)
Clinical Endocrinology, Vol. 101, Núm. 2, pp. 180-190
2023
2022
-
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Gut, Vol. 71, Núm. 9, pp. 1856-1866
2021
-
Expert consensus guidelines on minimally invasive donor hepatectomy for living donor liver transplantation from innovation to implementation: A joint initiative from the international laparoscopic liver society (ILLS) and the Asian-Pacific hepato-pancreato-biliary association (A-PHPBA)
Annals of Surgery, Vol. 273, Núm. 1, pp. 96-108
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310
-
Is chelation therapy a potential treatment for parkinson’s disease?
International Journal of Molecular Sciences, Vol. 22, Núm. 7
2020
-
Convergent evolution of zoonotic Brucella species toward the selective use of the pentose phosphate pathway
Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 42, pp. 26374-26381
-
Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial
Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197
2019
-
Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis
Hepatology Communications, Vol. 3, Núm. 7, pp. 867-882
2018
-
PEG-PGA enveloped octaarginine-peptide nanocomplexes: An oral peptide delivery strategy
Journal of Controlled Release, Vol. 276, pp. 125-139
2017
-
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
Scientific Reports, Vol. 7, Núm. 1
2016
-
70-Gene signature as an aid to treatment decisions in early-stage breast cancer
New England Journal of Medicine, Vol. 375, Núm. 8, pp. 717-729